{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:53:47Z","timestamp":1779288827572,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":1821,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.14283\/jpad.2019.30","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T18:57:25Z","timestamp":1614279445000},"page":"223-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The 2018 Revised FDA Guidance for Early Alzheimer's Disease: Establishing the Meaningfulness of Treatment Effects"],"prefix":"10.1016","volume":"6","author":[{"given":"Chris J.","family":"Edgar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Vradenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hassenstab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2019.30_bib1","author":"FDA"},{"key":"10.14283\/jpad.2019.30_bib2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","article-title":"Clinical Outcome Assessments: Conceptual Foundation \u2014 Report of the ISPOR Clinical Outcomes Assessment \u2014 Emerging Good Practices for Outcomes Research Task Force","volume":"18","author":"Walton","year":"2015","journal-title":"Value Heal"},{"issue":"4","key":"10.14283\/jpad.2019.30_bib3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1037\/neu0000156","article-title":"Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease","volume":"29","author":"Buckley","year":"2015","journal-title":"Neuropsychology"},{"issue":"6","key":"10.14283\/jpad.2019.30_bib4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1017\/S1041610211002766","article-title":"The process of decline in advanced activities of daily living: a qualitative explorative study in mild cognitive impairment","volume":"24","author":"De Vriendt","year":"2012","journal-title":"International Psychogeriatrics"},{"issue":"2","key":"10.14283\/jpad.2019.30_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/gps.1855","article-title":"Mild cognitive impairment: coping with an uncertain label","volume":"23","author":"Joosten-Weyn Banningh","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.14283\/jpad.2019.30_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jalz.2015.04.008","article-title":"Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase","volume":"12","author":"Gordon","year":"2016","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"6","key":"10.14283\/jpad.2019.30_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jalz.2011.08.006","article-title":"A new informant-based questionnaire for instrumental activities of daily living in dementia","volume":"8","author":"Sikkes","year":"2012","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.14283\/jpad.2019.30_bib8","first-page":"498","article-title":"The conceptual relevance of assessment measures in patients with mild\/mild-moderate Alzheimer\u2019s disease","volume":"10","author":"Hartry","year":"2018","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"10.14283\/jpad.2019.30_bib9","article-title":"Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational Considerations","author":"Richardson","year":"2018","journal-title":"Therapeutic Innovation and Regulatory Science"},{"issue":"9","key":"10.14283\/jpad.2019.30_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"8","key":"10.14283\/jpad.2019.30_bib11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The Preclinical Alzheimer Cognitive Composite","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurology"},{"key":"10.14283\/jpad.2019.30_bib12","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2017.13","article-title":"EU\/US\/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials","author":"Aisen","year":"2017","journal-title":"J Prev Alzheimer's Dis"},{"issue":"6","key":"10.14283\/jpad.2019.30_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/2168479017719934","article-title":"Use of Qualitative Data to Support Content Validity of Performance-Based Cognitive Outcome Assessments","volume":"51","author":"Edgar","year":"2017","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"10.14283\/jpad.2019.30_bib14","first-page":"85089","article-title":"Assessment of Clinical Meaningfulness of Endpoints in the Generation Program by the Insights to Model Alzheimer's Progression in Real Life (iMAP) Study","volume":"6","author":"Graf","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"10.14283\/jpad.2019.30_bib15","first-page":"P1522","article-title":"THE PATIENT VOICE: EXPLORING TREATMENT PREFERENCES IN PARTICIPANTS WITH MILD COGNITIVE CONCERNS TO INFORM REGULATORY DECISION MAKING","volume":"13","author":"Mansfield","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"13","key":"10.14283\/jpad.2019.30_bib16","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458514530489","article-title":"Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening","volume":"20","author":"Phillips","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.14283\/jpad.2019.30_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy\u2014Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value in Health"},{"key":"10.14283\/jpad.2019.30_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2017.06.1877","article-title":"Estimating clinically relevant change and difference thresholds for the clinical dementia rating: Sum of boxes (CDR-SB) for early Alzheimer's disease","author":"Edgar","year":"2017","journal-title":"Alzheimer's Dement"},{"issue":"2","key":"10.14283\/jpad.2019.30_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2011","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"3","key":"10.14283\/jpad.2019.30_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11136-014-0790-9","article-title":"Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers","volume":"24","author":"Cook","year":"2014","journal-title":"Quality of Life Research"},{"issue":"1","key":"10.14283\/jpad.2019.30_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11136-015-1058-8","article-title":"Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method","volume":"25","author":"Thissen","year":"2015","journal-title":"Quality of Life Research"},{"issue":"3","key":"10.14283\/jpad.2019.30_bib22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2478\/jee-2014-0027","article-title":"Ac Impedance Spectroscopy Of Al\/A-Sic\/C\u2013Si(P)\/Al Heterostructure under Illumination","volume":"65","author":"Pern\u00fd","year":"2014","journal-title":"Journal of Electrical Engineering"},{"issue":"10","key":"10.14283\/jpad.2019.30_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jalz.2017.02.005","article-title":"Clinical meaningfulness of Alzheimer\u2019s Disease Assessment Scale\u2013Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors","volume":"13","author":"Rockwood","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:43:14Z","timestamp":1736469794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724003200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2274580724003200"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2019.30","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2018 Revised FDA Guidance for Early Alzheimer's Disease: Establishing the Meaningfulness of Treatment Effects","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2019.30","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}